News and Updates from CAAT
November 11, 2021 10 am – 12 pm EST
10:00 Introduction 5 min (Marty Stephens, Founding Director of EBTC)
10:05 Keynote: History of EBT movement and application in diverse fields (Thomas Hartung, Professor of Evidence-based Toxicology, Johns Hopkins Bloomberg School of Public Health)
Presentations on use cases of Evidence-based Toxicology
10:20 History of implementation of SR methods at IRIS (Kris Thayer, US )
10:35 Certainty in evidence for environmental health claims (Holger Schunemann)
10:50 Systematic Review at EFSA (Didier Verloo, EFSA)
11:05 Harnessing Artificial Intelligence to Bridge the Systematic Method and Environmental Health Data Divide (Michelle Angrish, US EPA)
11:25 Panel with users of evidence: Moderated by Jack Fowle, President of EBTC Board of Trustees.
Bette Meek, University of Ottawa
Julija Filipovska, Independent
Tala Henry, US EPA
Richard Brown, WHO
Bennard von Ravenzwaay, BASF
11:45 Looking at the next decade for Evidence-based Toxicology : Katya Tsaioun
Early Career Scientist Award for New Approach Methods (NAMs) Development (€30,000)
Application period extended for our Early Career Scientists Award (30,000 €) for the Development of New Approach Methods (NAMs) to further the Application of Human-relevant Replacement Methods in Biomedical Research
The Animal Protection Commissioner of Berlin (and CAAT’s Director of the Beyond Classical Refinement Program) Kathrin Herrmann offers funding for an Early Career Scientists Award for the development of NAMs to actively support the shift from tradition-based animal experimentation to human-relevant health research. The Early Career Scientist Award is for a promising research proposal from an up-and-coming scientist that will advance the development and uptake of NAMs. The Award includes prize money of €30,000.
Deadline: November 1, 2021, 11.59 pm CET.
More information click here.
2-day Early Career Scientists Online Workshop on NAMs in Biomedical Research
November 22-23, 2021, 9am-12pm EST/ 3-6pm CET Online Workshop (via Zoom)
Deadline for applications: November 7, 2021
More information here
CAAT and the Animal Protection Commissioner of Berlin are inviting early career scientists for a two-day Online Workshop focusing on animal-free New Approach Methodologies (NAMs) in biomedical research. The program will include presentations and interactive sessions. Following the call for abstracts, up to ten early career scientists will be selected to present their own research involving NAMs. The program will also include a session with established scientists from academia, industry, government, and NGOs who will answer the participants’ questions and share advice and guidance on future careers in the field of non-animal methods. In another session, we will discuss topics such as how to tackle the ‘publish or perish’ trap, and where to find funding as well as ongoing training opportunities in NAMs.
The Workshop is free of charge. Please use the form on the website to apply and to submit your abstract (if you would like to present your research) via email to Dr. Kathrin Herrmann at firstname.lastname@example.org. Deadline is November 7th, 2021.
The Role of Public Awareness in the Replacement of Animals In Safety Testing
November 24-25, 2021 (1:00 pm - 4:00 pm UK time)
Dr Kathrin Herrmann, CAAT and Animal Protection Commissioner of Berlin, Germany and Dr Costanza Rovida, CAAT-Europe, will be presenting at the LUSH PRIZE CONFERENCE 2021
More information and free registration here
Systems engineering of Microphysiological Systems
December 9th 2021, 9 am – 1 pm EST
In preparation of the first MPS World Summit, we are meeting on-line on December 9th to discuss the advances in MPS technology.
The MPS World Summit is an effort of many collaborators:
9:00 Welcome, Thomas Hartung, JHU
9:05 Keynote Address: Donald Ingber, Wyss Institute, Harvard University
9:35 "MPS Hardware and Enabling Technologies" (short talks from submitted abstracts)
10:55 Break and poster voting
11:00 "Cell Models and Applications for MPS" (short talks from submitted abstracts)
12:20 Panel discussion and Q&A
Adrian Roth, Roche - moderator
Linda Griffith, Massachusetts Institute of Technology
Alysson Moutri, University of California San Diego
Peter Loskill, Tuebingen University
Uwe Marx, TissUse
Hiroshi Kimura, Tokai University
12:50 Young Investigator Travel Award announcement and closing remarks
Registration is open! Click here to register.
|American Society for Cellular and Computational Toxicology (ASCCT)
|CAPB Brown University
|Centre of Excellence in Body-on-Chip Research at Tampere University
|Charité – Universitätsmedizin Berlin
|CN Bio Innovations Limited
|Competence Centre TEDD
|European Food Safety Authority (EFSA)
|European Medical Agency (EMA)
|European Organ-On-Chip Society (EUROoCS)
|European Society for Alternatives to Animal Testing (EUSAAT)
|European Society of Toxicology (ESTIV)
|Health and Environmental Sciences Institute (HESI)
|Institute for human Organ and Disease Model Technologies (hDMT)
|Institute for the Advancement of Food and Nutrition Sciences (IAFNS)
|Johns Hopkins Center for Alternatives to Animal Testing (CAAT)
|MB Research Laboratories
|National Center for Advancing Translational Sciences (NCATS)
|National Interangency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)
|Roche Institute for Translational Bioengineering (ITB)
|Si-M (The Simulated Human- a joint research building of TU Berlin and Charité)
|Society for Laboratory Automation and Screening (SLAS)
|The North American 3Rs Collaborative (NA3RsC)
|U.S. Food & Drug Administration (FDA)
|University of Pittsburgh - Drug Discovery Institute
|University of Washington - Institute for Risk Analysis and Risk Communication
|Wake Forest Institute for Regenerative Medicine, USA
|Wyss Institute for Biologically Inspired Engineering at Harvard University
New article: “Autism in Three Dimensions: Using Brain Organoids to Study Potential Gene–Environment Interactions” for Environmental Health Perspectives (EHP)
Lena Smirnova and colleagues compared brain organoids containing a normal version of CHD8, the gene encoding chromodomain helicase DNA binding protein 8, with those containing the high-risk ASD mutation CHD8+/−. CHD8 is one of more than 50 genes associated with higher risk of ASD. The number of these genes, plus more than 50 well-supported additional genes with lower penetrance (i.e., a lower proportion of people with the mutation develop clinical symptoms), illustrates the genetic heterogeneity of ASD that contributes to its wide symptom variation.
The clinical heterogeneity of autism spectrum disorder (ASD) makes it difficult to match treatments to patients. The unique nature of ASD in humans has also hampered the use of animal models in drug development. Brain organoids, “miniature brains” derived from human cells, have emerged as a promising alternative strategy for understanding ASD. A recently published study in Environmental Health Perspectives suggests these organoids may also be well suited for modeling the gene–environment interactions that have long been suspected of increasing ASD risk.
Jean Knight, Costanza Rovida, Reinhard Kreiling [...] Thomas Hartung
Vol. 38 No. 4 (2021), pp. 653-668
Paul Locke, Mikalah Singer, Thomas Hartung
Vol. 38 No. 4 (2021), pp. 678-680
Read the complete issue here:
We recently published a new Altertox video about NAMs: episode 2: Replacing rabbits and horseshoe crab in pharmacopeia: the “human pyrogen testing
Find here the last article published in Voxeurope and written by our colleague Jeanne Laperrouze: https://voxeurop.eu/en/protecting-the-environment-with-flies-worms-and-the-theory-of-evolution/
Deadline: January 15, 2022
The applicants must fulfill the following criteria:
- The application should focus on the innovative development and / or application of animal-free antibodies for research or medical purposes
- The application can be for ongoing or completed projects
- The project must not contain any animal experiments or animal-derived products such as fetal calf serum (FCS), bovine serum albumin (BSA), milk powder, etc.
- The applicants must be based on the continent of Europe. Applicants from EU and non-EU member states in Europe are welcome to apply
- The applicants must be prepared to accept the prize at an event in Brussels in spring of 2022, and give a short presentation. Travel expenses will be covered
Prize amount and award ceremony
The prize amounts to €10.000 and can be awarded to an individual researcher or a researcher consortium, a university department, an industrial company or other type of research facility. The prize will be awarded at an event in Brussels in March/April 2022.
Please submit the following application documents in English:
Call for tender as PDF
- A project description containing title, abstract, short background, research aims, methodological procedures, time plan and project milestones (for ongoing projects) or outcomes of the project (for completed projects). The project description should be focused on the development or application of animal-free antibodies and it should include a declaration that no animal experiments were performed and no animal-derived materials were used, including in buffers, cell media, blotting reagents, etc. (up to 6 pages).
- A description of the applicant’s motivation to develop and / or use animal-free antibodies (1 page).
- A tabular curriculum vitae of the applicant with a publication list.
Contact person: Dr. Dilyana Filipova E-mail: email@example.com
1. EU Science Hub - European Commission: Better antibodies without using animals. 11.5.2020
2. Viegas Barroso JF et al. EURL ECVAM recommendation on non-animal-derived antibodies, Publications Office of the European Union, 2020
The CAAT Team